{"id":"W3044214090","doi":"10.1016/j.clon.2020.07.006","title":"Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK","year":2020,"lang":"en","type":"editorial","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Daiichi Sankyo Company; National Institute on Handicapped Research; Merck Sharp and Dohme; Health Technology Assessment Programme; Eisai; AstraZeneca France; Daiichi-Sankyo; National Institute for Health and Care Research; Puma Biotechnology; Les Laboratories Pierre Fabre; Genomic Health; Elsevier Foundation; Sanofi; Novartis; Celgene; Roche; Oncolytics Biotech; Cancer Research UK; Intas Pharmaceuticals; Department for Culture, Heritage and the Gaeltacht, Ireland; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Neratinib; Breast cancer; Internal medicine; Adjuvant therapy; Adjuvant; Cancer; Surgery; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.006019677,0.0002266864,0.001386247,0.0001333367,0.00004368731,0.00002123224,0.0007312664,0.001518876,0.0003151159],"category_scores_gemma":[0.00796966,0.0001288337,0.0002486901,0.0005917713,0.0006538184,0.00003378293,0.0001776534,0.005214163,0.0000285377],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009426087,"about_ca_system_score_gemma":0.007248363,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003173751,"about_ca_topic_score_gemma":0.005067379,"domain_scores_codex":[0.9941598,0.001748199,0.001901707,0.0005622985,0.001139367,0.0004886742],"domain_scores_gemma":[0.9873444,0.01109071,0.0005238692,0.000549774,0.0003497867,0.0001414348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00261449,0.0005242302,0.02038208,0.0001920791,0.00009062357,0.0003930557,0.001507531,0.00002600049,0.00002572052,0.00001907236,0.9062271,0.06799808],"study_design_scores_gemma":[0.005574158,0.004036556,0.2747389,0.0008532052,0.0001989976,0.00002443713,0.0005222066,0.0002541067,0.000006764548,0.00008809732,0.7135094,0.0001930739],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.07090271,0.00218097,0.00002422605,0.09703597,0.8218048,0.003213822,0.0004694205,0.00003211889,0.004336011],"genre_scores_gemma":[0.3265045,0.003112214,0.0001091325,0.001230958,0.6684028,0.0002901353,0.00008989879,0.00005669942,0.0002037188],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.2556018,"threshold_uncertainty_score":0.9997774,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1272786951343438,"score_gpt":0.5247389173070323,"score_spread":0.3974602221726884,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}